Processa Pharmaceuticals Inc (PCSA)

$2.32 -0.01 (-0.43%)
Market Cap 7.16M
Revenue (ttm) 0.00
Net Income (ttm) -11.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 58,900
Avg Vol 55,768
Day's Range N/A - N/A
Shares Out 2.27M
Stochastic %K 20%
Beta 1.05
Analysts Sell
Price Target $25.00

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 443 776 3133
Fax: 443 288 4420
Address:
7380 Coca Cola Drive, Suite 106, Hanover, United States
hbkstockislife
hbkstockislife Mar. 20 at 2:56 PM
$PCSA shorting a 5 million mc with data coming within next weeks ..wow shorts playing here
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 20 at 2:16 PM
$PCSA This thing has een shorted so heavily when its starts its accend the bears baiing will be enough to get to 10
0 · Reply
paok44
paok44 Mar. 20 at 2:53 AM
$PCSA Based on the 10k, the results of the survey were moved to the 2nd half of 2026 from the 1st that they told us in December? another 3 months, that is?
1 · Reply
TragicTwits
TragicTwits Mar. 19 at 5:42 PM
$PCSA gambled here
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 19 at 5:18 PM
$PCSA - Expecting interim breast cancer data in next few weeks. I anticipate company using the big pop on this to raise with Dreyfus as they continue their CHZ treasury program.
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 19 at 5:05 PM
$PCSA Starter position opened. 10k shares at 2.25/share. Thanks to whoever was impatient and dumped.
0 · Reply
Baraa_MD
Baraa_MD Mar. 19 at 4:27 PM
$PCSA what's happening in here?
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 19 at 4:16 PM
$PCSA may have to double down here!
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 18 at 10:38 PM
$PCSA - Crypto angle here starting to look interesting. Dreyfus surely has some plans for the company.
1 · Reply
StanlySmith
StanlySmith Mar. 18 at 9:14 PM
$PCSA see another 10K another offering? Looks like raising cash
0 · Reply
Latest News on PCSA
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 9:15 AM EST - 2 months ago

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Jan 5, 2026, 9:15 AM EST - 2 months ago

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Dec 17, 2025, 1:10 PM EST - 3 months ago

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Dec 17, 2025, 8:00 AM EST - 3 months ago

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Nov 5, 2025, 9:15 AM EST - 4 months ago

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Aug 7, 2025, 8:30 AM EDT - 8 months ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Processa Pharmaceuticals Provides Portfolio and Business Update

Jul 1, 2025, 9:00 AM EDT - 9 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 12:26 PM EDT - 9 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 17, 2025, 9:00 AM EDT - 9 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Jun 13, 2025, 8:00 AM EDT - 10 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025, 9:00 AM EDT - 10 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Feb 7, 2025, 8:00 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 30, 2025, 5:17 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

May 6, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 14, 2024, 1:00 PM EST - 2 years ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Feb 1, 2024, 4:22 PM EST - 2 years ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 2 years ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 11:29 AM EST - 2 years ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 25, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 19, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 18, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Jan 2, 2024, 5:06 PM EST - 2 years ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 19, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Dec 13, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Next Generation Chemotherapy: Improved Treatment for More Patients

Jun 14, 2023, 4:15 PM EDT - 3 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 22, 2023, 8:05 AM EDT - 3 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 18, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Apr 28, 2023, 8:15 AM EDT - 3 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 30, 2023, 4:01 PM EDT - 3 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 23, 2023, 8:30 AM EDT - 3 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

hbkstockislife
hbkstockislife Mar. 20 at 2:56 PM
$PCSA shorting a 5 million mc with data coming within next weeks ..wow shorts playing here
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 20 at 2:16 PM
$PCSA This thing has een shorted so heavily when its starts its accend the bears baiing will be enough to get to 10
0 · Reply
paok44
paok44 Mar. 20 at 2:53 AM
$PCSA Based on the 10k, the results of the survey were moved to the 2nd half of 2026 from the 1st that they told us in December? another 3 months, that is?
1 · Reply
TragicTwits
TragicTwits Mar. 19 at 5:42 PM
$PCSA gambled here
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 19 at 5:18 PM
$PCSA - Expecting interim breast cancer data in next few weeks. I anticipate company using the big pop on this to raise with Dreyfus as they continue their CHZ treasury program.
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 19 at 5:05 PM
$PCSA Starter position opened. 10k shares at 2.25/share. Thanks to whoever was impatient and dumped.
0 · Reply
Baraa_MD
Baraa_MD Mar. 19 at 4:27 PM
$PCSA what's happening in here?
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 19 at 4:16 PM
$PCSA may have to double down here!
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 18 at 10:38 PM
$PCSA - Crypto angle here starting to look interesting. Dreyfus surely has some plans for the company.
1 · Reply
StanlySmith
StanlySmith Mar. 18 at 9:14 PM
$PCSA see another 10K another offering? Looks like raising cash
0 · Reply
Goldengun23
Goldengun23 Mar. 17 at 6:29 PM
$PCSA cmon give us a moonshot to $40 one time
0 · Reply
smartmoney43
smartmoney43 Mar. 16 at 8:14 PM
$PCSA 😍😍
0 · Reply
Shallu
Shallu Mar. 16 at 4:11 PM
$PCSA huge buy signal……?☕️📈
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 16 at 4:09 PM
$PCSA - another strong day. News should be imminent.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 10:53 PM
$PCSA
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 13 at 3:30 PM
$PCSA - Kind of get a vibe some sort of news is coming premarket Monday.
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 12 at 5:06 PM
$PCSA adding
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 11 at 6:04 PM
$PCSA - Chart looks ready to "moon." Perhaps with the help of our 13% crypto holder Dreyfus.
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 11 at 3:29 PM
$PCSA - No matter anyone's opinion on the merits of this company you have to admit the stock grinding up with little to no selling is bullish ahead of any interim cancer data or crypto based announcement.
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 11 at 1:20 PM
$PCSA It will do nothing until it does, but when it does your to late. 0 to 100mph this stock will go. Im waiting patiently.
0 · Reply
Jwa68
Jwa68 Mar. 10 at 2:38 AM
$PCSA What happened David? I thought a man's word is supposed to be his bond?
0 · Reply
Jwa68
Jwa68 Mar. 9 at 3:06 AM
$PCSA Over-promise and under-deliver" occurs when expectations exceed reality, causing damaged trust and reputation. Driven by people-pleasing or unrealistic optimism, it leads to missed deadlines and poor quality, particularly in business relationships. It also leads to value destruction and shareholder losses.
0 · Reply